Form 990 for tax year 2025
Filed by DAVOS ALZHEIMERS COLLABORATIVE INC.
Totals
- Total revenue
- $12,470,622
- Total expenses
- $16,083,398
- Contributions and grants received
- $12,186,383
- Grants paid
- $3,542,155
- Program service revenue
- $60,000
- Investment income
- $224,239
- Other revenue
- $0
- Total assets, end of year
- $8,470,178
- Total liabilities, end of year
- $577,289
- Net assets or fund balances, end of year
- $7,892,889
- Program services expenses (Part IX)
- $14,834,609
- Management and general expenses
- $496,089
- Fundraising expenses
- $752,700
- Program service expenses (Part III)
- $14,834,609
Program services were 92.2% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.
Line items
Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.
Revenue
Part VIII, the statement of revenue.
-
1f · All other contributions, gifts and grants
$12,186,383
-
1g · Noncash contributions included above
$4,905,928
-
2a · Program service revenue: CONTRACT INCOME
total $60,000 · related or exempt $60,000
-
3 · Investment income
total $224,239 · excluded $224,239
Functional expenses
Part IX, the statement of functional expenses.
-
1 · Grants to domestic organizations and governments
total $2,323,750 · program services $2,323,750
-
3 · Grants to foreign organizations and individuals
total $1,218,405 · program services $1,218,405
-
11a · Fees: management
total $997,537 · program services $927,417 · management and general $38,528 · fundraising $31,592
-
11b · Fees: legal
total $183,815 · program services $170,894 · management and general $7,100 · fundraising $5,821
-
11c · Fees: accounting
total $207,171 · management and general $207,171
-
11g · Fees: other
total $9,577,907 · program services $9,099,836 · management and general $168,089 · fundraising $309,982
-
12 · Advertising and promotion
total $195,886 · program services $159,518 · management and general $200 · fundraising $36,168
-
13 · Office expenses
total $19,081 · program services $3,797 · management and general $15,085 · fundraising $199
-
14 · Information technology
total $11,082 · program services $2,205 · management and general $8,763 · fundraising $114
-
17 · Travel
total $1,298,502 · program services $918,767 · management and general $11,430 · fundraising $368,305
-
23 · Insurance
total $21,251 · program services $4,228 · management and general $16,804 · fundraising $219
-
24a · Other expenses: BAD DEBT
total $25,000 · program services $4,974 · management and general $19,768 · fundraising $258
-
24b · Other expenses: SUBSCRIPTION FEES
total $2,238 · program services $445 · management and general $1,770 · fundraising $23
-
24c · Other expenses: MISCELLANEOUS
total $1,773 · program services $373 · management and general $1,381 · fundraising $19
Balance sheet
Part X, book values.
-
1 · Cash, non-interest-bearing
beginning of year $9,007,029 · end of year $952,856
-
2 · Savings and temporary cash investments
end of year $5,988,759
-
3 · Pledges and grants receivable
beginning of year $3,895,504 · end of year $1,427,470
-
9 · Prepaid expenses and deferred charges
beginning of year $469,884 · end of year $101,093
-
17 · Accounts payable and accrued expenses
beginning of year $1,870,549 · end of year $577,289
-
27 · Net assets without donor restrictions
beginning of year $7,659,407 · end of year $3,998,205
-
28 · Net assets with donor restrictions
beginning of year $3,842,461 · end of year $3,894,684
Mission and programs · 2025
Mission
DAC IS LEADING THE LARGEST GLOBAL RESPONSE OF ITS KIND, DRIVING SCIENTIFIC DISCOVERY AND ALIGNING HEALTH SYSTEMS TO HELP PEOPLE WORLDWIDE, INCLUDING THOSE IN LOW RESOURCED ENVIRONMENTS LEFT OUT OF PREVIOUS EFFORTS TO FIGHT ALZHEIMER'S. (SEE SCHEDULE O)WE ARE COMMITTED TO TRANSFORMING ALZHEIMER'S RESEARCH, PREVENTION AND CARE THROUGH PROVEN PRIVATE-PUBLIC MODELS, SUCH AS GAVI, CEPI AND THE GLOBAL FUND.
Activities or mission (Part I)
SEE PART III LINE 1.
-
THE DAVOS ALZHEIMER'S COLLABORATIVE'S SYSTEM PREPAREDNESS PROGRAM AIMS TO STRENGTHEN HEALTHCARE SYSTEMS' ABILITY TO IDENTIFY AND ADDRESS ALZHEIMER'S DISEASE (AD) AND RELATED DEMENTIAS (ADRD) EARLY. KEY INITIATIVES INCLUDE THE EARLY DETECTION FELLOWSHIP, WHICH OFFERS TECHNICAL ASSISTANCE AND FUNDING TO HEALTHCARE ORGANIZATIONS (HCOS) TO IMPLEMENT THE EARLY DETECTION BLUEPRINT, FOSTERING COLLABORATION AMONG SELECTED SITES TO OVERCOME BARRIERS AND ENHANCE EARLY DETECTION. THE PROGRAM ALSO INCLUDES THE BRAIN HEALTH NAVIGATOR INITIATIVE, DESIGNED TO PILOT A BRAIN HEALTH NAVIGATOR MODEL IN SIX HCOS TO SUPPORT TIMELY CARE FOR PATIENTS WITH COGNITIVE DECLINE. ADDITIONALLY, THE ACCURATE DIAGNOSIS PROGRAM AIMS TO INCREASE THE USE OF NEW DIAGNOSTIC TOOLS, HELPING HEALTHCARE SYSTEMS ADOPT MORE EFFECTIVE METHODS FOR DIAGNOSING AD/ADRD. THESE EFFORTS ARE SUPPORTED BY SIGNIFICANT FUNDING AND ARE INTENDED TO IMPROVE SYSTEM PREPAREDNESS THROUGH OUTREACH, TRAINING, AND THE CREATION OF PRACTICAL TOOLKITS FOR HEALTHCARE PROVIDERS.OVERALL, OUTPUTS INCLUDE PEER-REVIEWED PUBLICATIONS, SYMPOSIUMS, POLICY COMMUNICATIONS, AND AN OPEN-ACCESS "BLUEPRINT" FOR AD/ADRD EARLY DETECTION AND SYSTEM PREPAREDNESS. DAC ALSO COLLABORATES WITH OTHER ORGANIZATIONS TO ADDRESS COMMON BARRIERS AND PROMOTE BEST PRACTICES ACROSS HEALTH SYSTEMS.
Expenses $13,167,569 · Grants $3,538,155
-
THE DAVOS ALZHEIMER'S COLLABORATIVE'S GLOBAL COHORT DEVELOPMENT PROGRAM FOCUSES ON BUILDING A DIVERSE AND SUSTAINABLE NETWORK OF COHORTS TO ADVANCE ALZHEIMER'S DISEASE (AD) AND RELATED DEMENTIAS (ADRD) RESEARCH. THIS INCLUDES PARTNERSHIPS SUCH AS THE COLLABORATION WITH AGA KHAN UNIVERSITY IN NAIROBI, KENYA, WHERE COGNITIVE TESTS, SALIVA-BASED POLYGENIC RISK SCORES, AND DIGITAL COGNITIVE ASSESSMENTS ARE BEING VALIDATED IN EAST AFRICAN POPULATIONS TO CREATE A CLINICAL TRIAL-READY COHORT. IN SOUTH KOREA, DAC HAS ACQUIRED BLOOD SAMPLES FROM 300 PARTICIPANTS IN A HIGHLY CHARACTERIZED COHORT, ADVANCING THE VALIDATION OF BLOOD-BASED BIOMARKERS (BBMS) FOR GLOBAL USE. THE PROJECT ALSO INCLUDES ACCESS TO 1,000 BLOOD SAMPLES FROM A LONG-STANDING COHORT IN THE LATAM/CARIBBEAN REGION FOR AD BLOOD BIOMARKER VALIDATION, AS WELL AS A LARGE-SCALE CLINICAL TRIAL RECRUITMENT EFFORT IN THE DOMINICAN REPUBLIC, WITH OVER 14,000 PARTICIPANTS ACROSS URBAN AND RURAL SETTINGS.FURTHER EXPANDING GLOBAL RESEARCH, DAC IS DEVELOPING SCALABLE APPROACHES IN EGYPT FOR EARLY DETECTION, MONITORING, AND RISK REDUCTION OF AD, WHILE IN INDIA, THE "EYE-DEA STUDY" IS USING CATARACT SURGERY CLINICS TO ASSESS OCULAR, SPEECH, AND OLFACTORY BIOMARKERS RELATED TO COGNITIVE IMPAIRMENT. IN CHILE, DAC IS COLLECTING A WIDE RANGE OF DATA FROM A 9,000-PERSON COHORT TO GENERATE LOCAL VALIDATION DATA FOR BLOOD BIOMARKERS AND DIGITAL COGNITIVE ASSESSMENTS, PARTICULARLY FOCUSING ON THE IMPACT OF PESTICIDE USE AND EXPOSURE TO NEUROTOXINS. THESE EFFORTS ARE HELPING TO ENSURE THAT AD RESEARCH IS INCLUSIVE OF DIVERSE POPULATIONS AND ADAPTABLE TO LOCAL SETTINGS, WITH THE AIM OF IMPROVING EARLY DETECTION, DIAGNOSIS, AND TREATMENT ON A GLOBAL SCALE.
Expenses $1,667,040 · Grants $4,000 · Revenue $60,000
-
THE DAVOS ALZHEIMER'S COLLABORATIVE'S GLOBAL CLINICAL TRIAL PROGRAM IS MAINTAINING A NETWORK OF MORE THAN 30 EUROPEAN SITES ORGANIZED TO ACCELERATE STUDIES AND IMPLEMENT NOVEL TRIAL DESIGNS. THIS EFFORT IS PART OF DAC'S BROADER GOAL TO BUILD INFRASTRUCTURE FOR FUTURE PHARMACOLOGICAL AND NON-PHARMACOLOGICAL TRIALS GLOBALLY. THROUGH THE GLOBAL COHORT DEVELOPMENT PROGRAM, DAC IS WORKING TO CREATE CLINICAL TRIAL-READY POPULATIONS BY 2026, ENSURING THAT DIVERSE AND WELL-CHARACTERIZED COHORTS ARE PREPARED FOR BOTH TYPES OF INTERVENTIONS. THIS WILL EXPAND OPPORTUNITIES FOR GLOBAL CLINICAL TRIALS, ENHANCING THE ABILITY TO TEST NEW TREATMENTS AND APPROACHES IN ALZHEIMER'S DISEASE (AD) AND RELATED DEMENTIAS (ADRD) ACROSS VARIED POPULATIONS AND SETTINGS.
As filed on the 2025 return. The filer continues this part on Schedule O, which is not shown here.
Listed in Part VII
-
George VradenburgGEORGE VRADENBURG
CHAIR & PRESIDENT
- Total calculated
- $0
- Hours/week
- 20 + 2 related
-
Andrew HolzapfelANDREW HOLZAPFEL
COO (SEE SCHEDULE O)
- Total calculated
- $0
- Hours/week
- 30 + 3 related
-
Freda Lewis HallFREDA LEWIS HALL
TREASURER
- Total calculated
- $0
- Hours/week
- 1 + 1 related
Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those.
Grants on this return
-
THE CLEVELAND CLINIC FOUNDATION
$650,000
SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE
-
$187,500
SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE
-
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
$165,000
SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE
-
$100,000
SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE
-
$100,000
SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE
-
$100,000
SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE
-
SHARP REES-STEAL MEDICAL GROUP INC
$100,000
SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE
-
$100,000
SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE
-
$82,500
FELLOWSHIP
-
$82,500
FELLOWSHIP
The 10 largest by cash amount. The API serves every itemized grant.
Activities outside the United States
From Schedule F of this return, as filed.
- Offices (line 3c)
- 0
- Employees, agents and contractors (line 3c)
- 43
- Expenditures and investments (line 3c)
- $4,564,426
At most 25 lines of each part are listed here. Schedule F names no grantee, so each line is a region and its money.
Activities by region (Part I)
| Region | Offices | Employees | Activity | Specific services | Expenditures |
|---|---|---|---|---|---|
| EAST ASIA AND THE PACIFIC | 0 | 0 | GRANTS TO RECIPIENTS LOCATED IN THE REGION | — | $230,855 |
| EUROPE | 0 | 0 | GRANTS TO RECIPIENTS LOCATED IN THE REGION | — | $985,550 |
| SOUTH AMERICA | 0 | 0 | GRANTS TO RECIPIENTS LOCATED IN THE REGION | — | $2,000 |
| EAST ASIA AND THE PACIFIC | 0 | 1 | PROGRAM SERVICES | SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE | $25,000 |
| EUROPE | 0 | 19 | PROGRAM SERVICES | PROFESSIONAL FEES, RESEARCH SERVICES, MARKETING, TRAVEL LEGAL SERVICES | $1,696,041 |
| MIDDLE EAST AND NORTH AFRICA | 0 | 2 | PROGRAM SERVICES | RESEARCH SITE AND RESEARCH SERVICES | $168,115 |
| NORTH AMERICA | 0 | 5 | PROGRAM SERVICES | PROGRAM SERVICES AND RESEARCH SITE | $640,503 |
| SOUTH AMERICA | 0 | 4 | PROGRAM SERVICES, RESEARCH SERVICES, RESEARCH SITE AND TRAVEL | RESEARCH SITE, SPONSORSHIP AND PROGRAM SERVICES | $572,520 |
| SOUTH ASIA | 0 | 2 | RESEARCH SERVICES | RESEARCH SITE, RESEARCH SERVICES AND TRAVEL | $197,782 |
| SUB-SAHARAN AFRICA | 0 | 10 | PROGRAM SERVICES | RESEARCH SERVICES, MARKETING AND TRAVEL | $46,060 |
Grants to organizations, by region (Part II)
The purpose of each grant is not shown.
| Region | Cash grants | Manner of disbursement | Noncash assistance | Noncash description | Valuation |
|---|---|---|---|---|---|
| EAST ASIA & THE PACIFIC | $230,855 | — | $0 | — | — |
| EUROPE | $325,000 | — | $0 | — | — |
| EUROPE | $649,550 | — | $0 | — | — |
| EUROPE | $11,000 | — | $0 | — | — |
- Grantees recognized as charities or with a 501(c)(3) equivalency letter (Part II line 2)
- 4
- Other grantees (Part II line 3)
- 0
- Transferred property to a foreign corporation during the year (line 1)
- Yes
- Had an interest in a foreign trust (line 2)
- No
- Owned an interest in a foreign corporation (line 3)
- No
- Was a shareholder of a passive foreign investment company or qualified electing fund (line 4)
- No
- Owned an interest in a foreign partnership (line 5)
- No
- Had operations in or related to a boycotting country (line 6)
- No
Related organizations on this return
Schedule R Part II: tax-exempt organizations related to the filer by control. It does not record shared board members or money.
-
DAVOS ALZHEIMER'S COLLABORATIVE (GENEVE)
N/A · PROMOTE HEALTH BY DEVELOPING RESEARCH ON BRAIN HEALTH.. · SZ · controlled entity
Directly controlled by DAC
Provenance
- Return type
- form_990
- Tax year
- 2025
- Filed
- 29 May 2026
- IRS schema version
- 2025v4.1
- Source object
- 202631499349301118
Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.
The source document this was parsed from is served over the API, which is where bulk and document access live.